Organometallic Compounds in Cancer Therapy: Past Lessons and Future Directions

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Organometallic Compounds in Cancer Therapy: Past Lessons and Future Directions



Anti-Cancer Agents in Medicinal Chemistry, 14(9): 1199-1212.

Author(s): Pedro Martins, Mara Marques, Lidia Coito, Armando J.L. Pombeiro, Pedro Viana Baptista and Alexandra R Fernandes.

Affiliation: Departamento de Ciencias da Vida, Faculdade de Ciencias e Tecnologia da Universidade Nova de Lisboa, Campus de Caparica, 2829-516 Caparica, Portugal.

Abstract

Over the past few years, modern medicinal chemistry has evolved towards providing us new and alternative chemotherapeutic compounds with high cytotoxicity towards tumor cells, alongside with reduced side effects in cancer patients. Organometallic compounds and their unique physic-chemical properties typically used in homogenous catalysis are now being translated as potential candidates for medical purposes. Their structural diversity, ligand exchange, redox and catalytic properties make them promising drug candidates for cancer therapy. Over the last decade this area has witnessed a steady growth and a few organometallic compounds have in fact already entered clinical trials, emphasizing its increasing importance and clinical relevance. Here we intend to stress out the different applications of organometallic compounds in medicine with emphasis on cancer therapy, as well as address setbacks regarding formulation issues, systemic toxicity and off-target effects. Advantages over classical coordination metal complexes, their nanovectorisation and specific molecular targets are also discussed.




Keywords:

Cancer therapy, clinical trials, M-arenes, M-carbenes, M-carbonyls, metallocenes, nanovectorisation, organometallics compounds.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 14
Issue Number: 9
First Page: 1199
Last Page: 1212
Page Count: 14
DOI: 10.2174/1871520614666140829124925
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science